| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8286072 | Parkinsonism & Related Disorders | 2016 | 7 Pages |
Abstract
LSPD patients show a slight response to a supra-maximal levodopa dose, which is greater if dyskinesia are present, but it is frequently associated with adverse effects. A decrease in levodopa response is a potential marker of disease progression in LSPD.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
Margherita Fabbri, Miguel Coelho, Daisy Abreu, Leonor Correia Guedes, Mario M. Rosa, Nilza Costa, Angelo Antonini, Joaquim J. Ferreira,